Patents by Inventor Phillippe Baudier

Phillippe Baudier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN
    Publication number: 20130217769
    Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e.
    Type: Application
    Filed: December 13, 2012
    Publication date: August 22, 2013
    Applicants: GALEPHAR M/F
    Inventors: Francis Vanderbist, Cécile Servais, Phillippe Baudier
  • Pharmaceutical semi-solid composition of isotretinoin
    Patent number: 8367102
    Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: February 5, 2013
    Assignee: Galephar Pharmaceutical Research, Inc.
    Inventors: Francis Vanderbist, Cécile Servais, Phillippe Baudier
  • Anti-inflammatory inhalation pharmaceutical composition
    Publication number: 20090041681
    Abstract: The present invention is directed to the discovery of the anti-inflammatory properties of basic amino salts of acetylcysteine when administered directly to the lungs and/or the nose. This observed inflammation reduction in the lungs and/or the nasal cavity is confirmed by the diminution of at least one of the following inflammatory markers IL_6 and IL_8 and/or the increase in the lungs and/or the nasal cavity of the anti-inflammatory markers IL_10. The present invention also discloses pharmaceutical compositions for pulmonary and/or nasal administration of basic amino salts of acetylcysteine characterised that they have anti-inflammatory properties and may be useful to treat inflammatory lung and/or nasal conditions found in illnesses such as COPD, asthma, cystic fibrosis and the like.
    Type: Application
    Filed: October 14, 2008
    Publication date: February 12, 2009
    Inventors: Arthur Deboeck, Francis Vanderbist, Phillippe Baudier
  • Pharmaceutical semi-sold composition of isotretinoin
    Publication number: 20080171084
    Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e.
    Type: Application
    Filed: August 22, 2007
    Publication date: July 17, 2008
    Applicant: GALEPHAR M/F
    Inventors: Francis VANDERBIST, Cecile SERVAIS, Phillippe BAUDIER
  • Anti-inflamatory inhalation pharmaceutical composition
    Publication number: 20080107746
    Abstract: The present invention is directed to the discovery of the anti-inflammatory properties of basic amino salts of acetylcysteine when administered directly to the lungs and/or the nose. This observed inflammation reduction in the lungs and/or the nasal cavity is confirmed by the diminution of at least one of the following inflammatory markers IL_6 and IL_8 and/or the increase in the lungs and/or the nasal cavity of the anti-inflammatory markers IL_10. The present invention also discloses pharmaceutical compositions for pulmonary and/or nasal administration of basic amino salts of acetylcysteine characterised that they have anti-inflammatory properties and may be useful to treat inflammatory lung and/or nasal conditions found in illnesses such as COPD, asthma, cystic fibrosis and the like.
    Type: Application
    Filed: December 31, 2007
    Publication date: May 8, 2008
    Inventors: Arthur Deboeck, Francis Vanderbist, Phillippe Baudier
  • Anti-inflamatory inhalation pharmaceutical composition
    Publication number: 20050154060
    Abstract: The present invention is directed to the discovery of the anti-inflammatory properties of basic amino salts of acetylcysteine when administered directly to the lungs and/or the nose. This observed inflammation reduction in the lungs and/or the nasal cavity is confirmed by the diminution of at least one of the following inflammatory markers IL_6 and IL_8 and/or the increase in the lungs and/or the nasal cavity of the anti-inflammatory markers IL_10. The present invention also discloses pharmaceutical compositions for pulmonary and/or nasal administration of basic amino salts of acetylcysteine characterised that they have anti-inflammatory properties and may be useful to treat inflammatory lung and/or nasal conditions found in illnesses such as COPD, asthma, cystic fibrosis and the like.
    Type: Application
    Filed: December 13, 2004
    Publication date: July 14, 2005
    Applicant: Galephar Pharmaceutical Research, Inc.
    Inventors: Arthur Deboeck, Francis Vanderbist, Phillippe Baudier